×
About 5,530 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  1,441 results

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for th...
https://doi.org/10.1111/dth.15077
Dermatologic Therapy; Anna C, Atzori L et. al.

Aug 2nd, 2021 - Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. Th...

Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis.
https://doi.org/10.1159/000517018
Dermatology (Basel, Switzerland); Gisondi P, Geat D et. al.

Jul 30th, 2021 - Plaque psoriasis has been associated with anxiety, depression, suicidal ideation and various personality traits. However, studies on hypochondriasis, i.e. the belief of serious illness despite having no or only mild symptoms, are currently scarce....

Dimethyl fumarate treatment for psoriasis in a real-life setting: a multicentric retros...
https://doi.org/10.1111/dth.15066
Dermatologic Therapy; Corazza M, Odorici G et. al.

Jul 23rd, 2021 - Dimethyl fumarate (DMF) is a fumaric acid esters derivate approved for plaque psoriasis as first-line systemic therapy. It has been available in Italy since 2017 and an increasing number of patients are treated with this drug. To evaluate DMF effe...

Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020).
https://doi.org/10.1080/09546634.2021.1950601
The Journal of Dermatological Treatment; Fatani MIA, Hamadah IRA et. al.

Jul 22nd, 2021 - Psoriasis is a common chronic and complex inflammatory skin disease that affects over 125 million people worldwide. Management of psoriasis in daily clinical practice in Saudi Arabia is variable. Local preferences for management differ, which may ...

Uncoupling protein 2 and dynamin-related protein 1 mRNA expressions as genetic markers ...
https://doi.org/10.1111/ijd.15788
International Journal of Dermatology; Shehata WA, Hammam MA et. al.

Jul 22nd, 2021 - Psoriasis is a long-lasting, inflammatory disease of the skin with not fully understood pathogenesis. Uncoupling protein 2 (UCP2) and dynamin-related protein 1 (Drp1) are the main mitochondrial regulatory proteins implicated in various inflammator...

see more →

Guidelines  1 results

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

see more →

Drugs  123 results see all →

Clinicaltrials.gov  245 results

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT00521339

May 7th, 2020 - This is a phase 2, multicenter, open-label, study to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy of Apremilast in participants with recalcitrant plaque-type psoriasis. Approximately 31 participants were enrol...

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT02576678

May 7th, 2020 - Each subject will undergo a screening period of up to 5 weeks, a treatment period of 2 weeks with PK sample collection, and an extension treatment period of 48 weeks, to allow subjects access to apremilast treatment if medically appropriate (follo...

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03392168

Apr 24th, 2020 - There are 2 cohorts of subjects. Cohort 1 is a single dose study of ARQ-151 0.5% cream applied to 25 cm2 of psoriatic plaque(s) in up to 8 psoriasis subjects. Cohort 2 is a parallel group, double blind, vehicle controlled study in which ARQ-151 cr...

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
https://clinicaltrials.gov/ct2/show/NCT03721172

Apr 20th, 2020 - The study will consist of four phases: Screening Phase - up to 35 days Double-blind Placebo-controlled Phase - Weeks 0 to 16 - Subjects will be randomly assigned to either apremilast 30 mg tablets orally BID or placebo tablets (identical in appear...

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03701763

Apr 17th, 2020 - Treatment will be assigned by weight with subjects 20 kg to < 50 kg receiving apremilast 20 mg BID or placebo BID and subjects ≥ 50 kg receiving apremilast 30 mg BID or placebo BID. Total study duration is up to 71 weeks. Subjects completing all 5...

see more →

News  401 results

Fast Five Quiz: Plaque Psoriasis Presentation and Diagnosis
https://www.medscape.com/viewarticle/929579

Jul 9th, 2021 - Psoriasis is a chronic, immune-mediated inflammatory skin disease. Globally, approximately 125 million people have psoriasis, which manifests in several ways (ie, plaque, flexural, guttate, pustular, or erythrodermic psoriasis). Plaque psoriasis i...

Fast Five Quiz: Plaque Psoriasis Management
https://www.medscape.com/viewarticle/923304

Jul 9th, 2021 - Plaque psoriasis is the most common form of psoriasis, a chronic inflammatory skin disorder that affects approximately 125 million individuals worldwide. It exerts a considerable burden on affected patients, including decreased quality of life and...

Biologic Treatment Mitigates PsA Risk in Patients With Psoriasis, Study Finds
https://www.medscape.com/viewarticle/953693

Jun 24th, 2021 - Patients with psoriasis treated with biological disease-modifying antirheumatic drugs had a significantly lower incidence of psoriatic arthritis (PsA) compared with those treated with phototherapy, in a study of 464 adults. Epidemiologic data show...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://reference.medscape.com/viewarticle/929577

Jun 14th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://www.medscape.com/viewarticle/929577

Jun 14th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

see more →

Patient Education  1 results see all →